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Treatment and survival of patients with inoperable Non-small-cell lung cancer in 1997 (n¼117) and 2001 (n¼126), before and after
the introduction of a multidisciplinary team, was examined in a single centre. There were no differences in age, sex and extent of
deprivation between the two years. However, in 2001, 23% of patients received chemotherapy treatment compared with 7% in
1997 (Po0.001). Median survival in 2001 was 6.6 months compared with 3.2 months in 1997 (Po0.001).
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Lung cancer is the commonest cause of cancer death in North
America and Western Europe. For example, each year in the UK
there are approximately 38000 new cases and approximately
33000 deaths (Cancerstats, 2003; www.cancerresearchuk.org).
Non-small-cell lung cancer (NSCLC) accounts for approximately
three-quarters of all lung cancer cases. Survival remains poor. For
example, in Scotland, the median survival for patients with NSCLC
is approximately 5 months (Gregor et al, 2001). Therefore, it is
important to ensure that the treatment of these patients is optimal
and that active treatment is offered to all patients who may benefit
(Gregor et al, 2001; Jack et al, 2003).
This rationale has driven the introduction of specialised care by
multi-disciplinary teams to improve the delivery of care and
treatment to patients with lung cancer (Selby et al, 1996; Alberts
et al, 2003). However, to date, few studies have specifically
examined the effect of the multidisciplinary team on the treatment
and survival of patients with NSCLC.
The aim of the present study was to examine the impact of the
introduction of a multidisciplinary team on survival of patients
with inoperable NSCLC.
PATIENTS
Patients diagnosed with inoperable NSCLC (stage III/IV) at the
Royal Infirmary, Glasgow, prior to and following the introduction
of a multidisciplinary team in 1998 were included in the study. The
multi-disciplinary team consisted of two respiratory physicians,
two surgeons, a medical oncologist, a clinical oncologist, a palliative
care physician, a radiologist and a specialist respiratory nurse.
Information was abstracted from the case notes by a specially
trained research nurse (LMF). Data for the year 1997 prior to the
introduction of a multidisciplinary team were collected retro-
spectively and those for 2001 were collected prospectively. Patient
details, including age, sex, extent of deprivation, tumour type,
stage and type of treatment were obtained from the patient’s
records.
The extent of deprivation was defined using the Carstairs Index,
an area-based measure derived from the 1991 census data based on
the postcode of residence at diagnosis. (Carstairs and Morris,
1991).
Patients were staged in accordance with the American Thoracic
Society TNM classification on the basis of clinical findings, chest
X-ray, and, where appropriate, bronchoscopy, liver ultrasound,
isotope bone scan and computerised tomography of the thorax
(Mountain, 1991).
Patients were considered to have undergone active treatment if
they received chemotherapy (mainly cisplatin based) and/or
radical radiotherapy. Patients receiving palliative radiotherapy
and/or palliative care (symptom control) were considered to have
had palliative treatment.
The study was approved by the Research Ethics Committee of
the Royal Infirmary, Glasgow.
Statistics
Comparisons between groups of patients (1997 and 2001) were
carried out using contingency table analysis (w
2) as appropriate.
Univariate survival analysis was performed using the Kaplan–
Meier method with the logrank test. Deaths up to 30 September
2004 were included in the analysis. Analysis was performed using
SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
Of 323 (167 patients in 1997 and 156 patients in 2001) patients with
histological or cytological evidence of NSCLC, 243 (117 patients in
1997 and 126 patients in 2001) patients underwent formal staging
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s(Fisher’s exact test, P¼0.035). The characteristics of patients
(n¼243) with inoperable NSCLC (stage III/IV) treated in 1997 and
2001 are shown in Table 1.
Overall, the majority of patients were over 60 years of age, male,
deprived, and had stage IV disease. There were no differences in
age, sex and extent of deprivation between the two years. However,
there was a decrease in the proportion of patients presenting with
stage IIIa disease in 2001 (P¼0.015).
In 2001, 23% of patients received chemotherapy treatment
compared with 7% of patients in 1997 (Po0.001). In 2001, 44% of
patients received palliative care only compared with 58% of
patients in 1997 (P¼0.045). On follow-up, 116 of the 117 patients
diagnosed in 1997 had died compared with 116 of 126 patients
diagnosed in 2001 (Fisher’s exact test, P¼0.011). Median survival
was significantly higher in patients treated in 2001 compared with
those treated in 1997 (6.6 vs 3.2 months, Po0.001).
DISCUSSION
The present study, to our knowledge, is the first to examine the
impact of the introduction of a multidisciplinary team on the
survival of patients with inoperable NSCLC presenting to a single
centre.
In the present study, the introduction of a multidisciplinary
team was associated with a change in the treatment of patients with
inoperable NSCLC. In particular, more patients received che-
motherapy and fewer patients received palliative care only.
Although the proportion of patients who received chemotherapy
following the introduction of the multidisciplinary team appears
low, more than half of the patients studied are from an area of
multiple deprivation. This is not surprising, since eight of the 15
most deprived areas in the UK are in Glasgow (Gordon et al, 1999).
A possible explanation of the results of the present study is that
indications for chemotherapy in the earlier period (1997) may not
have been as strong as in the latter period (2001). However, in
1997, the use of chemotherapy in this centre was primarily
determined by a medical oncologist (DJD) according to referral,
indication and clinical need. At this time, there was good evidence
of the benefit of chemotherapy in patients with inoperable NSCLC
(Non-Small Cell Lung Cancer Collaborative Group, 1995).
A significant problem in studies of this type is the phenomenon
of ‘stage drift’, whereby in the latter study period patients are
diagnosed at an earlier point in their disease course and so appear
to have an improved outcome. In the present study, we chose to
study only those patients with a clinical stage defined as inoperable
in both time periods in an attempt to minimise this problem.
Consistent with this approach was that similar numbers of patients
were studied and that age, sex and deprivation were similar in the
two time periods, independent of stage.
The introduction of a multidisciplinary team was associated
with an increase in the proportion of patients being staged,
presenting with stage IIIb disease and receiving chemotherapy.
This was associated with a doubling of survival in patients with
stage III disease. Although there was evidence of ‘stage drift’, it was
towards more advanced disease and therefore would not account
for the improvement in survival. Furthermore, the improvement in
the survival of the cohort as a whole would suggest that, in the
present study, treatment improved survival. Therefore, the results
of the present study appear to confirm the value of a multi-
disciplinary approach to the management of patients with
inoperable NSCLC.
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Table 1 Baseline characteristics of patients (n¼243) with inoperable
NSCLC (stage III/IV) in 1997 and 2001
1997 2001
Patients 117
(100%)
Patients 126
(100%) P-value
Age
o60 years 21 (18) 23 (18)
460 years 96 (82) 103 (82) 0.951
Sex
Male 77 (66) 75 (60)
Female 40 (34) 51 (40) 0.312
Extent of deprivation
Affluent 1 (1) 7 (6)
Intermediate 44 (38) 46 (36)
Deprived 72 (61) 73 (58) 0.425
Stage
IIIa 20 (17) 8 (6)
IIIb 14 (12) 27 (22)
IV 83 (71) 91 (72) 0.010
Treatment
Radical radiotherapy 6 (5) 3 (2)
Chemotherapy 8 (7) 29 (23)
Palliative radiotherapy 35 (30) 38 (30)
Palliative care only 68 (58) 56 (44) 0.003
Median survival (months) 3.2 (2.4–4.1) 6.6 (3.7–9.5) o0.001
NSCLC¼non-small-cell lung cancer.
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